TIBET PHARMACEUTICALS, INC. (a British Virgin Islands company) Minimum Offering: 2,500,000 Common Shares Maximum Offering: 3,000,000 Common Shares ($ per share) PLACEMENT AGREEMENTPlacement Agreement • December 16th, 2010 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations • Virginia
The undersigned, Tibet Pharmaceuticals, Inc., a British Virgin Islands company (the “Company”), hereby confirms its agreement with you as follows:
TIBET PHARMACEUTICALS, INC. WARRANT AGREEMENTWarrant Agreement • October 18th, 2010 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations • Virginia
Tibet Pharmaceuticals, Inc., a British Virgin Islands company (the “Company”), agrees to issue and sell to you a warrant (the “Warrant”) to purchase the number of common shares of the Company set forth herein, subject to the terms and conditions contained herein.
ESCROW AGREEMENTEscrow Agreement • December 16th, 2010 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations • Virginia
This Escrow Agreement is made and entered into as of the th day of , 2010, by and among ANDERSON & STRUDWICK, INCORPORATED, a Virginia corporation (the “Placement Agent”), TIBET PHARMACEUTICALS, INC., a British Virgin Islands company (the “Company”) and SUNTRUST BANK (the “Escrow Agent”).
Make Good Escrow AgreementGood Escrow Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc. • Virginia
THIS MAKE GOOD ESCROW AGREEMENT (the “Make Good Agreement”), dated effective as of , 2010, is entered into by and among Shangri-La Tibetan Pharmaceuticals, Inc., a British Virgin Islands corporation (the “Company”); Anderson & Strudwick, Inc. (“A&S”); Ms. Hong Yu and Mr. Taylor Gao in their individual capacities (collectively the “Make Good Pledgors” and each individually a “Make Good Pledgor”); and SunTrust Bank, N.A., as escrow agent (“Escrow Agent”).
SHAREHOLDERS’ VOTING PROXY AGREEMENT BETWEEN HONG YU LUO GA YANG XIAOBEI AND YIBO INFORMATION CONSULTING (SHENZHEN) CO., LTD. March 26, 2010 SHENZHEN, CHINAShareholders’ Voting Proxy Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
This Shareholders’ Voting Proxy Agreement (the “Agreement”) is entered into on March 26, 2010 between the following parties in Shenzhen:
Lock-Up AgreementLock-Up Agreement • October 18th, 2010 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations
The undersigned understands that Anderson & Strudwick, Incorporated (the “Placement Agent”), proposes to enter into a Placement Agreement with Tibet Pharmaceuticals, Inc. (the “Company”), providing for the public offering (the “Offering”), by the Placement Agent of a minimum of 2,500,000 common shares and a maximum of 3,000,000 common shares (the “Shares”).
PLEDGE OF EQUITY AGREEMENT BETWEEN HONG YU LUO GA YANG XIAOBEI AND YIBO INFORMATION CONSULTING (SHENZHEN) CO., LTD. March 26, 2010 SHENZHEN, CHINAEquity Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
Therefore, in accordance with applicable laws and regulations of the People’s Republic of China, the Parties hereto reach the Agreement through friendly negotiation on the principle of equality and mutual benefit and abide by the following terms and conditions
Lock-Up AgreementLock-Up Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
The undersigned understands that Anderson & Strudwick, Incorporated (the “Placement Agent”), proposes to enter into a Placement Agreement with Shangri-La Tibetan Pharmaceuticals, Inc. (the “Company”), providing for the public offering (the “Offering”), by the Placement Agent of a minimum of 1,500,000 common shares and a maximum of 1,875,000 common shares (the “Shares”).
RETAINER CONTRACTRetainer Contract • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
Yunnan Shangri-La Tibetan Pharmaceutical Group Limited, a company legally incorporated under the laws of People’s Republic of China, having a registered address at 53 Niwang Road, Shangri-La County, Yunnan Province, China. (hereinafter referred to as “SHANGRI-LA”)
EMPLOYMENT AGREEMENTEmployment Agreement • June 10th, 2011 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into June 6 , 2011 (the “Effective Date”), by and between TIBET PHARMACEUTICALS, INC., a company incorporated and existing under the laws of the British Virgin Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as the “Company Group”), and Yu Hong, an individual (the “Executive”).
Entrusted Management Agreement Between Hong Yu Luo Ga Yang Xiaobei Yunnan Shangri-La Tibetan Pharmaceutical Group Limited and Yibo Information Consulting (Shenzhen) Co., Ltd. March 26, 2010 Shenzhen, ChinaEntrusted Management Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
Party B: Yibo Information Consulting (Shenzhen) Co., Ltd., is a company registered in Shenzhen, PRC, and the registration number of its legal and valid Business License is 440301503371231 and the legal registered address is B#6D11, Zhongshen Garden, South Caitian Rd., Futian, Shenzhen, China.
EXCLUSIVE OPTION AGREEMENT AMONG YIBO INFORMATION CONSULTING (SHENZHEN) CO., LTD. AND HONG YU LUO GA YANG XIAOBEI AND YUNNAN SHANGRI-LA TIBETAN PHARMACEUTICAL GROUP LIMITED March 26, 2010Exclusive Option Agreement • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
In this Agreement, Party A, Party B and Party C are called collectively as the “Parties” and each of them is called as the “Party”.
LETTER OF ENGAGEMENT Tibet Pharmaceuticals, Inc. October 12, 2010Stock Issuance Agreement • October 18th, 2010 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The following sets forth the agreement (this “Agreement”) for the engagement of Trilogy Capital Partners, Inc., (“Trilogy”) by Tibet Pharmaceuticals, Inc. (“Tibet” or the “Company”):
RETAINER CONTRACTRetainer Contract • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
Yunnan Shangri-La Tibetan Pharmaceutical Group Limited, a company legally incorporated under the laws of People’s Republic of China, having a registered address at 53 Niwang Road, Shangri-La County, Yunnan Province, China. (hereinafter referred to as “SHANGRI-LA”)
Termination AgreementTermination Agreement • June 10th, 2011 • Tibet Pharmaceuticals, Inc. • Pharmaceutical preparations
Tibet Pharmaceuticals, Inc., a company legally incorporated under the laws of British Virgin Islands and listed in NASDAQ, having a principal executive office at Room 1701, 17/F 90 Jaffe Rd. Wanchai, Hong Kong (hereinafter referred to as “TBET”)
Translation of Agreement on Prescription and Industrialization Development of Tibetan MedicineShangri-La Tibetan Pharmaceuticals, Inc. • May 14th, 2010
With a view to effectively carry out the project of “Modern Research & Industrialization Development of Chinese Traditional Medicine” as well as “Prescription and Industrialization Development of Tibetan Medicine” advocated by the Life Science and Technology Centre of Science and Technology Ministry, both parties, through flexibility research and friendly negotiation, entered into the Agreement herein as the following terms and conditions on the basis of sincere cooperation and mutual development.
RETAINER CONTRACTRetainer Contract • May 14th, 2010 • Shangri-La Tibetan Pharmaceuticals, Inc.
Yunnan Shangri-La Tibetan Pharmaceutical Group Limited, a company legally incorporated under the laws of People’s Republic of China, having a registered address at 53 Niwang Road, Shangri-La County, Yunnan Province, China. (hereinafter referred to as “SHANGRI-LA”)
Translation of Agreement on Research into Tibetan Medicine Pharmacology and EffectShangri-La Tibetan Pharmaceuticals, Inc. • May 14th, 2010
In order to support West China Development Drive, promote the Tibetan medicine modernization strategy and help those frontier backwards areas to alleviate poverty, Party B makes a resolution to provide support and assistance in Party A’s current products as well as its on-going research products by analysis of the Pharmacology and Effect. Therefore both parties, through friendly consultation, agree upon the following terms and conditions:
